April 1993

Somatostatin Analogue Inhibits Intestinal Regeneration

Author Affiliations

From the Surgical Service, Omaha (Neb) Veterans Affairs Medical Center (Dr Thompson), and the Departments of Surgery (Drs Thompson and Nguyen) and Medicine (Dr Harty), University of Nebraska Medical Center, Omaha.

Arch Surg. 1993;128(4):385-389. doi:10.1001/archsurg.1993.01420160023002

• Somatostatin analogue octreotide inhibits intestinal absorption and motility but its effect on epithelial cell migration and proliferation remains unclear. Our aim was to determine the effect of octreotide on parameters of intestinal regeneration, including epidermal growth factor (EGF)—induced changes. Thirty rabbits had full-thickness ileal defects patched with cecal serosa surface. Group 1 were controls. Groups 2 and 3 received 100 μg and 1000 μg, respectively, of subcutaneous octreotide daily. Group 4 received EGF at 1.5 μg/kg per hour via subcutaneous miniosmotic pump, and group 5 received both octreotide (1000 μg/d and EGF (1.5 μg/kg per hour). Octreotide at 100 μg/d did not inhibit epithelial cell migration or proliferation at 7 days. Octreotide at 1000 μg/d inhibited normal but not EGF-stimulated cell migration. Octreotide decreased EGF-stimulated but not normal proliferation. Octreotide impairs epithelial cell migration in a dose-dependent manner. Octreotide inhibits EGF-stimulated proliferative activity but not EGF-stimulated migration. Prolonged administration of octreotide may adversely affect normal and adaptive intestinal regeneration by both direct and indirect effects.

(Arch Surg. 1993;128:385-389)